Gan & Lee’s first big cross-border deal aids Menarini push into obesity

Italian pharma Menarini is making its first push into obesity via a licensing deal with Beijing-based Gan & Lee for twice-monthly GLP-1R agonist bofanglutide, which has showed strong efficacy data compared with market leader Zepbound tirzepatide. 

The deal marks the first major out-licensing deal for Gan & Lee Pharmaceuticals (Shanghai:603087) from its innovative pipeline, which is primarily focused on metabolic diseases, with a Western biopharma. ...